Literature DB >> 17617387

Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis.

Jill M Weimer1, Jared W Benedict, Yasser M Elshatory, Douglas W Short, Denia Ramirez-Montealegre, Deborah A Ryan, Noreen A Alexander, Howard J Federoff, Jonathan D Cooper, David A Pearce.   

Abstract

Batten disease, or juvenile neuronal ceroid lipofuscinosis (JNCL), results from mutations in the CLN3 gene. This disorder presents clinically around the age of 5 years with visual deficits progressing to include seizures, cognitive impairment, motor deterioration, hallucinations, and premature death by the third to fourth decade of life. The motor deficits include coordination and gait abnormalities, myoclonic jerks, inability to initiate movements, and spasticity. Previous work from our laboratory has identified an early reduction in catechol-O-methyltransferase (COMT), an enzyme responsible for the efficient degradation of dopamine. Alterations in the kinetics of dopamine metabolism could cause the accumulation of undegraded or unsequestered dopamine leading to the formation of toxic dopamine intermediates. We report an imbalance in the catabolism of dopamine in 3 month Cln3(-/-) mice persisting through 9 months of age that may be causal to oxidative damage within the striatum at 9 months of age. Combined with the previously reported inflammatory changes and loss of post-synaptic D1alpha receptors, this could facilitate cell loss in striatal projection regions and underlie a general locomotion deficit that becomes apparent at 12 months of age in Cln3(-/-) mice. This study provides evidence for early changes in the kinetics of COMT in the Cln3(-/-) mouse striatum, affecting the turnover of dopamine, likely leading to neuron loss and motor deficits. These data provide novel insights into the basis of motor deficits in JNCL and how alterations in dopamine catabolism may result in oxidative damage and localized neuronal loss in this disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617387      PMCID: PMC4790084          DOI: 10.1016/j.brainres.2007.05.018

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  48 in total

Review 1.  Catechol-O-methyl transferase: pharmacological aspects and physiological role.

Authors:  H C Guldberg; C A Marsden
Journal:  Pharmacol Rev       Date:  1975-06       Impact factor: 25.468

2.  Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis.

Authors:  Catherine Kielar; Lucy Maddox; Ellen Bible; Charlie C Pontikis; Shannon L Macauley; Megan A Griffey; Michael Wong; Mark S Sands; Jonathan D Cooper
Journal:  Neurobiol Dis       Date:  2006-10-12       Impact factor: 5.996

Review 3.  Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis.

Authors:  Jin-Bo Fan; Chang-Shun Zhang; Niu-Fan Gu; Xing-Wang Li; Wei-Wei Sun; Hong-Yan Wang; Guo-Yin Feng; David St Clair; Lin He
Journal:  Biol Psychiatry       Date:  2005-01-15       Impact factor: 13.382

4.  [18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis.

Authors:  H M Ruottinen; J O Rinne; M Haaparanta; O Solin; J Bergman; V J Oikonen; I Järvelä; P Santavuori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

Review 5.  Methionine oxidation, alpha-synuclein and Parkinson's disease.

Authors:  Charles B Glaser; Ghiam Yamin; Vladimir N Uversky; Anthony L Fink
Journal:  Biochim Biophys Acta       Date:  2004-11-25

6.  Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected].

Authors:  H M Mitchison; D J Bernard; N D Greene; J D Cooper; M A Junaid; R K Pullarkat; N de Vos; M H Breuning; J W Owens; W C Mobley; R M Gardiner; B D Lake; P E Taschner; R L Nussbaum
Journal:  Neurobiol Dis       Date:  1999-10       Impact factor: 5.996

7.  Protein carbonyl groups as biomarkers of oxidative stress.

Authors:  Isabella Dalle-Donne; Ranieri Rossi; Daniela Giustarini; Aldo Milzani; Roberto Colombo
Journal:  Clin Chim Acta       Date:  2003-03       Impact factor: 3.786

8.  A favorable response to antiparkinsonian treatment in juvenile neuronal ceroid lipofuscinosis.

Authors:  L E Aberg; J O Rinne; I Rajantie; P Santavuori
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

9.  Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment.

Authors:  Silvana Galderisi; Mario Maj; Brian Kirkpatrick; Paola Piccardi; Armida Mucci; Giordano Invernizzi; Alessandro Rossi; Stefano Pini; Antonio Vita; Paolo Cassano; Paolo Stratta; Giovanni Severino; Maria Del Zompo
Journal:  Neuropsychobiology       Date:  2005-07-19       Impact factor: 2.328

10.  Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice.

Authors:  Hiroko Koike; P Alexander Arguello; Mirna Kvajo; Maria Karayiorgou; Joseph A Gogos
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-16       Impact factor: 11.205

View more
  14 in total

1.  Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease.

Authors:  Attila D Kovács; Angelika Saje; Andrew Wong; Serena Ramji; Jonathan D Cooper; David A Pearce
Journal:  Neuropharmacology       Date:  2012-06-06       Impact factor: 5.250

2.  Neuropeptide changes and neuroactive amino acids in CSF from humans and sheep with neuronal ceroid lipofuscinoses (NCLs, Batten disease).

Authors:  Graham W Kay; Marcel M Verbeek; Julie M Furlong; Michèl A A P Willemsen; David N Palmer
Journal:  Neurochem Int       Date:  2009-08-05       Impact factor: 3.921

3.  A Case-controlled Investigation of Pain Experience and Sensory Function in Neuronal Ceroid Lipofuscinosis.

Authors:  Chantel C Barney; John Hoch; Breanne Byiers; Adele Dimian; Frank J Symons
Journal:  Clin J Pain       Date:  2015-11       Impact factor: 3.442

Review 4.  Astrocytes and lysosomal storage diseases.

Authors:  K V Rama Rao; T Kielian
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

5.  A novel interaction of CLN3 with nonmuscle myosin-IIB and defects in cell motility of Cln3(-/-) cells.

Authors:  Amanda L Getty; Jared W Benedict; David A Pearce
Journal:  Exp Cell Res       Date:  2010-09-17       Impact factor: 3.905

6.  Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis.

Authors:  Jill M Weimer; Jared W Benedict; Amanda L Getty; Charlie C Pontikis; Ming J Lim; Jonathan D Cooper; David A Pearce
Journal:  Brain Res       Date:  2009-02-20       Impact factor: 3.252

Review 7.  Juvenile neuronal ceroid lipofuscinosis (JNCL) and the eye.

Authors:  Sara Bozorg; Denia Ramirez-Montealegre; Mina Chung; David A Pearce
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

Review 8.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

9.  Rapid and Progressive Regional Brain Atrophy in CLN6 Batten Disease Affected Sheep Measured with Longitudinal Magnetic Resonance Imaging.

Authors:  Stephen J Sawiak; Sunthara Rajan Perumal; Skye R Rudiger; Loren Matthews; Nadia L Mitchell; Clive J McLaughlan; C Simon Bawden; David N Palmer; Timothy Kuchel; A Jennifer Morton
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

10.  A murine model of variant late infantile ceroid lipofuscinosis recapitulates behavioral and pathological phenotypes of human disease.

Authors:  Jeremy P Morgan; Helen Magee; Andrew Wong; Tarah Nelson; Bettina Koch; Jonathan D Cooper; Jill M Weimer
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.